Routine annual meeting results, no immediate trading catalyst. Monitor for any subsequent capital raise or share issuance under the newly increased authorized capital.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $1.74entry
- T+1 · 6mo ago +1.72%α +0.89% · $1.77
- T+5 · 6mo ago 0.00%α −1.50% · $1.74
- T+20 · 6mo ago −1.15%α −4.29% · $1.72
- T+60 · 4mo ago −6.90%α −10.73% · $1.62
Price Chart
How similar events traded
Executive Summary
Chemomab Therapeutics filed a 6-K reporting results of its annual general meeting held on May 5, 2026. Shareholders approved the re-election of directors, compensation policy, an increase in authorized share capital, and reappointment of auditors. This is routine governance with no material financial impact.
Key Facts
- Re-elected Neil Cohen and Dr. Claude Nicaise as Class II directors
- Approved compensation policy for office holders and directors
- Approved increase in authorized share capital and amended articles accordingly
- Re-appointed Somekh Chaikin (KPMG) as independent auditor for FY2026
Financial Impact
No material financial impact; authorized share increase allows future capital raises but no immediate dilution
Risk Factors
- Potential future dilution from increased authorized capital if shares are issued
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002423 |
| Document: 0001178913-26-002423-index-headers.html | 0001178913-26-002423 |
| Document: 0001178913-26-002423-index.html | 0001178913-26-002423 |
| Document: 0001178913-26-002423.txt | 0001178913-26-002423 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers